Company intelligence / Profile preview
Virogin Biotech
Vancouver, British Columbia, Canadavirogin.com ↗
- Ownership
- Private
- Employees
- ~100
- Development stage
- Other
01
Overview
Virogin Biotech has two platforms: oncolytic HSV-1 and mRNA-based therapeutics. Their most advanced asset is in Phase 2 clinical trials, with other candidates in various stages of development. Their approach uses a heterologous prime-boost mechanism to elicit robust anti-tumor immune responses against solid tumors.
- Therapeutic areas
- Oncology
- Modalities
- Oncolytic virusesmRNA vaccinesSelf-amplifying RNA (saRNA)
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
03
Partnerships
China National Biotec Group (CNBG)Sinopharm
Beyond the preview
Go deeper on Virogin Biotech.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Virogin Biotech.